{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:22:26Z","timestamp":1780539746151,"version":"3.54.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Novo Nordisk Fonden, Denmark"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-06718-y","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:38:33Z","timestamp":1751384313000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Functional immune reconstitution after allogeneic hematopoietic stem cell transplantation in myeloablative and non-myeloablative conditioned patients"],"prefix":"10.1038","volume":"15","author":[{"given":"Patrick Terrence","family":"Brooks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"Minculescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Svanberg Teglgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Jakob","family":"Hartling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Antonio","family":"Salado-Jimena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone Smidstrup","family":"Friis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Kornblit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Schj\u00f8dt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren Lykke","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels Smedegaard","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne Dam","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Lundgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne Vibeke","family":"Marquart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Klingen","family":"Gjaerde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Sengel\u00f8v","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisse Rye","family":"Ostrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"6718_CR1","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41409-019-0516-2","volume":"54","author":"RF Duarte","year":"2019","unstructured":"Duarte, R. F. et al. Indications for Haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: Current practice in europe, 2019. Bone Marrow Transpl. 54, 1525\u20131552 (2019).","journal-title":"Bone Marrow Transpl."},{"key":"6718_CR2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","volume":"124","author":"B Gyurkocza","year":"2014","unstructured":"Gyurkocza, B. & Sandmaier, B. M. Conditioning regimens for hematopoietic cell transplantation: One size does not fit all. Blood 124, 344\u2013353 (2014).","journal-title":"Blood"},{"key":"6718_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jtct.2024.01.075","volume":"30","author":"MQ Salas","year":"2024","unstructured":"Salas, M. Q. et al. Outcomes of antithymocyte Globulin-Post-Transplantation Cyclophosphamide-Cyclosporine-Based versus antithymocyte Globulin-Based prophylaxis for 10\/10 HLA-Matched unrelated donor allogeneic hematopoietic cell transplantation. Transpl. Cell. Ther. 30, 1\u201313 (2024).","journal-title":"Transpl. Cell. Ther."},{"key":"6718_CR4","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","volume":"15","author":"S Giralt","year":"2009","unstructured":"Giralt, S. et al. Reduced-Intensity conditioning regimen workshop: Defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol. Blood Marrow Transpl. 15, 367\u2013369 (2009).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"6718_CR5","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","volume":"55","author":"A Spyridonidis","year":"2020","unstructured":"Spyridonidis, A. et al. Redefining and measuring transplant conditioning intensity in current era: A study in acute myeloid leukemia patients. Bone Marrow Transpl. 55, 1114\u20131125 (2020).","journal-title":"Bone Marrow Transpl."},{"key":"6718_CR6","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.3324\/haematol.2014.105981","volume":"99","author":"C Oudin","year":"2014","unstructured":"Oudin, C. et al. Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies. Haematologica 99, 1762\u20131768 (2014).","journal-title":"Haematologica"},{"key":"6718_CR7","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1080\/10428190701671051","volume":"48","author":"A Shimoni","year":"2007","unstructured":"Shimoni, A. et al. Fludarabine and treosulfan: A novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes. Leuk. Lymphoma. 48, 2352\u20132359 (2007).","journal-title":"Leuk. Lymphoma"},{"key":"6718_CR8","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.3324\/haematol.2020.268839","volume":"106","author":"N Gagelmann","year":"2021","unstructured":"Gagelmann, N. & Kr\u00f6ger, N. Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: Can we recommend when and for whom in 2021? Haematologica 106, 1794\u20131804 (2021).","journal-title":"Haematologica"},{"key":"6718_CR9","unstructured":"Cooper, J. P. et al. Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades. 106, 1599\u20131607 (2021)."},{"key":"6718_CR10","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.jcyt.2023.05.012","volume":"25","author":"AG Troullioud Lucas","year":"2023","unstructured":"Troullioud Lucas, A. G. et al. Early immune reconstitution as predictor for outcomes after allogeneic hematopoietic cell transplant; a tri-institutional analysis. Cytotherapy 25, 977\u2013985 (2023).","journal-title":"Cytotherapy"},{"key":"6718_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2016.00507","volume":"7","author":"J Ogonek","year":"2016","unstructured":"Ogonek, J. et al. Immune reconstitution after allogeneic hematopoietic stem cell transplantation. Front. Immunol. 7, 1\u201315 (2016).","journal-title":"Front. Immunol."},{"key":"6718_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fped.2021.786017","volume":"9","author":"A Yanir","year":"2022","unstructured":"Yanir, A., Schulz, A., Lawitschka, A., Nierkens, S. & Eyrich, M. Immune reconstitution after allogeneic Haematopoietic cell transplantation: From observational studies to targeted interventions. Front. Pediatr. 9, 1\u201325 (2022).","journal-title":"Front. Pediatr."},{"key":"6718_CR13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jcyt.2021.09.011","volume":"24","author":"A Bertaina","year":"2022","unstructured":"Bertaina, A. et al. An ISCT stem cell engineering committee position statement on immune reconstitution: The importance of predictable and modifiable milestones of immune reconstitution to transplant outcomes. Cytotherapy 24, 385\u2013392 (2022).","journal-title":"Cytotherapy"},{"key":"6718_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/sji.13042","volume":"94","author":"LK Gj\u00e6rde","year":"2021","unstructured":"Gj\u00e6rde, L. K. et al. Functional immune reconstitution early after allogeneic Haematopoietic cell transplantation: A comparison of pre- and post-transplantation cytokine responses in stimulated whole blood. Scand. J. Immunol. 94, 1\u201311 (2021).","journal-title":"Scand. J. Immunol."},{"key":"6718_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2015.00101","volume":"6","author":"TV Brennan","year":"2015","unstructured":"Brennan, T. V., Rendell, V. R. & Yang, Y. Innate immune activation by tissue injury and cell death in the setting of hematopoietic stem cell transplantation. Front. Immunol. 6, 1\u20139 (2015).","journal-title":"Front. Immunol."},{"key":"6718_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1146\/annurev-immunol-102119-073227","volume":"39","author":"GR Hill","year":"2021","unstructured":"Hill, G. R., Betts, B. C., Tkachev, V., Kean, L. S. & Blazar, B. R. Current concepts and advances in Graft-Versus-Host disease immunology. Annu. Rev. Immunol. 39, 19\u201349 (2021).","journal-title":"Annu. Rev. Immunol."},{"key":"6718_CR17","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/j.bbmt.2014.05.025","volume":"20","author":"J Koreth","year":"2014","unstructured":"Koreth, J. et al. Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival. Biol. Blood Marrow Transpl. 20, 1516\u20131521 (2014).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"6718_CR18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.cca.2020.10.034","volume":"512","author":"L Pettersson","year":"2021","unstructured":"Pettersson, L. et al. Development and performance of a next generation sequencing (NGS) assay for monitoring of mixed chimerism. Clin. Chim. Acta. 512, 40\u201348 (2021).","journal-title":"Clin. Chim. Acta"},{"key":"6718_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-019-4207-9","volume":"19","author":"CH Drabe","year":"2019","unstructured":"Drabe, C. H. et al. Immune function as predictor of infectious complications and clinical outcome in patients undergoing solid organ transplantation (the immunemo:sot study): A prospective non-interventional observational trial. BMC Infect. Dis. 19, 1\u20138 (2019).","journal-title":"BMC Infect. Dis."},{"key":"6718_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s43856-022-00178-5","volume":"2","author":"R Svanberg","year":"2022","unstructured":"Svanberg, R. et al. Early stimulated immune responses predict clinical disease severity in hospitalized COVID-19 patients. Commun. Med. 2, 1\u201315 (2022).","journal-title":"Commun. Med."},{"key":"6718_CR21","doi-asserted-by":"crossref","unstructured":"Ronit, A. et al. Compartmental immunophenotyping in COVID-19 ARDS: A case series. J Allergy Clin. Immunol 147, (2021).","DOI":"10.1016\/j.jaci.2020.09.009"},{"key":"6718_CR22","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.cell.2019.10.005","volume":"179","author":"V Gorgoulis","year":"2019","unstructured":"Gorgoulis, V. et al. Cellular senescence: defining a path forward. Cell 179, 813\u2013827 (2019).","journal-title":"Cell"},{"key":"6718_CR23","doi-asserted-by":"crossref","unstructured":"Liu, Z. et al. Immunosenescence: molecular mechanisms and diseases. Signal Transduct. Target. Ther 8, (2023).","DOI":"10.1038\/s41392-023-01451-2"},{"key":"6718_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2021.738204","volume":"12","author":"F Matteini","year":"2021","unstructured":"Matteini, F., Mulaw, M. A. & Florian, M. C. Aging of the hematopoietic stem cell niche: new tools to answer an old question. Front. Immunol. 12, 1\u201321 (2021).","journal-title":"Front. Immunol."},{"key":"6718_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.radonc.2015.11.012","volume":"118","author":"C Wilke","year":"2016","unstructured":"Wilke, C. et al. Marrow damage and hematopoietic recovery following allogeneic bone marrow transplantation for acute leukemias: effect of radiation dose and conditioning regimen. Radiother Oncol. 118, 65\u201371 (2016).","journal-title":"Radiother Oncol."},{"key":"6718_CR26","doi-asserted-by":"crossref","unstructured":"Gooptu, M. & Antin, J. H. G. V. H. D. Prophylaxis Front. Immunol. 12, 1\u201313 (2021). (2020).","DOI":"10.3389\/fimmu.2021.605726"},{"key":"6718_CR27","doi-asserted-by":"crossref","unstructured":"Hamilton, B. K. Current approaches to prevent and treat GVHD after allogeneic stem cell transplantation. Hematol. (United States) 228\u2013235 (2018). (2018).","DOI":"10.1182\/asheducation-2018.1.228"},{"key":"6718_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-28797-3","author":"JT Gea-banacloche","year":"2016","unstructured":"Gea-banacloche, J. T. & Infections Transpl. Infect. doi:https:\/\/doi.org\/10.1007\/978-3-319-28797-3. (2016).","journal-title":"Transpl. Infect."},{"key":"6718_CR29","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1093\/jac\/dkac025","volume":"77","author":"M Miller","year":"2022","unstructured":"Miller, M. & Singer, M. Do antibiotics cause mitochondrial and immune cell dysfunction? A literature review. J. Antimicrob. Chemother. 77, 1218\u20131227 (2022).","journal-title":"J. Antimicrob. Chemother."},{"key":"6718_CR30","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.bbmt.2016.12.630","volume":"23","author":"HK Miller","year":"2017","unstructured":"Miller, H. K. et al. Infectious risk after allogeneic hematopoietic cell transplantation complicated by acute Graft-versus-Host disease. Biol. Blood Marrow Transpl. 23, 522\u2013528 (2017).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"6718_CR31","doi-asserted-by":"crossref","unstructured":"Gj\u00e6rde, L. I., Moser, C. & Sengel\u00f8v, H. Epidemiology of bloodstream infections after myeloablative and non-myeloablative allogeneic hematopoietic stem cell transplantation: A single-center cohort study. Transpl Infect. Dis 19, (2017).","DOI":"10.1111\/tid.12730"},{"key":"6718_CR32","doi-asserted-by":"crossref","unstructured":"Minculescu, L. et al. Improved Relapse-Free survival in patients with high natural killer cell doses in grafts and during early immune reconstitution after allogeneic stem cell transplantation. Front Immunol 11, (2020).","DOI":"10.3389\/fimmu.2020.01068"},{"key":"6718_CR33","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41577-020-00457-z","volume":"21","author":"E Velardi","year":"2021","unstructured":"Velardi, E., Tsai, J. J. & van den Brink, M. R. M. T cell regeneration after immunological injury. Nat. Rev. Immunol. 21, 277\u2013291 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"6718_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12071974","volume":"12","author":"L Dekker","year":"2020","unstructured":"Dekker, L., de Koning, C., Lindemans, C. & Nierkens, S. Reconstitution of t cell subsets following allogeneic hematopoietic cell transplantation. Cancers (Basel). 12, 1\u201321 (2020).","journal-title":"Cancers (Basel)"},{"key":"6718_CR35","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.bbmt.2015.08.028","volume":"22","author":"C de Koning","year":"2016","unstructured":"de Koning, C., Plantinga, M., Besseling, P., Boelens, J. J. & Nierkens, S. Immune reconstitution after allogeneic hematopoietic cell transplantation in children. Biol. Blood Marrow Transpl. 22, 195\u2013206 (2016).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"6718_CR36","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1182\/blood.2022017267","volume":"141","author":"F Karl","year":"2023","unstructured":"Karl, F. et al. Oxidative DNA damage in reconstituting T cells is associated with relapse and inferior survival after allo-SCT. Blood 141, 1626\u20131639 (2023).","journal-title":"Blood"},{"key":"6718_CR37","doi-asserted-by":"crossref","unstructured":"Noh, J. Y., Yoon, S. R., Kim, T. D., Choi, I. & Jung, H. Toll-Like Receptors in Natural Killer Cells and Their Application for Immunotherapy. J. Immunol. Res. (2020). (2020).","DOI":"10.1155\/2020\/2045860"},{"key":"6718_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2022.1005031","volume":"13","author":"MU Mushtaq","year":"2022","unstructured":"Mushtaq, M. U. et al. Impact of natural killer cells on outcomes after allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis. Front. Immunol. 13, 1\u201313 (2022).","journal-title":"Front. Immunol."},{"key":"6718_CR39","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1016\/j.bbmt.2016.09.006","volume":"22","author":"L Minculescu","year":"2016","unstructured":"Minculescu, L. et al. Early natural killer cell reconstitution predicts overall survival in T cell\u2013Replete allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transpl. 22, 2187\u20132193 (2016).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"6718_CR40","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1016\/j.bbmt.2014.07.003","volume":"20","author":"R Reshef","year":"2014","unstructured":"Reshef, R. et al. Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning. Biol. Blood Marrow Transpl. 20, 1758\u20131766 (2014).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"6718_CR41","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1182\/bloodadvances.2018025502","volume":"3","author":"FAM Kinsella","year":"2019","unstructured":"Kinsella, F. A. M. et al. Mixed chimerism established by hematopoietic stem cell transplantation is maintained by host and donor T regulatory cells. Blood Adv. 3, 734\u2013743 (2019).","journal-title":"Blood Adv."},{"key":"6718_CR42","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.3324\/haematol.2011.043810","volume":"96","author":"T Ruutu","year":"2011","unstructured":"Ruutu, T. et al. Reduced-toxicity conditioning with Treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes:final results of an international prospective phase II trial. Haematologica 96, 1344\u20131350 (2011).","journal-title":"Haematologica"},{"key":"6718_CR43","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.bbmt.2016.11.023","volume":"23","author":"I Sakellari","year":"2017","unstructured":"Sakellari, I. et al. Survival advantage and comparable toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based conditioning regimen in myelodysplastic syndrome and acute myeloid leukemia patients after allogeneic hematopoietic cell transplantatio. Biol. Blood Marrow Transpl. 23, 445\u2013451 (2017).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"6718_CR44","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1182\/blood.2019000952","volume":"136","author":"GR Hill","year":"2020","unstructured":"Hill, G. R. & Koyama, M. Cytokines and costimulation in acute graft-versus-host disease. Blood 136, 418\u2013428 (2020).","journal-title":"Blood"},{"key":"6718_CR45","doi-asserted-by":"crossref","unstructured":"Simonetta, F. et al. Dynamics of expression of programmed cell death protein-1 (PD-1) on T cells after allogeneic hematopoietic stem cell transplantation. Front Immunol 10, (2019).","DOI":"10.3389\/fimmu.2019.01034"},{"key":"6718_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.01997","volume":"10","author":"L Minculescu","year":"2019","unstructured":"Minculescu, L. et al. Improved overall survival, relapse-free-survival, and less graft-vs.-host-disease in patients with high immune reconstitution of TCR gamma delta cells 2 months after allogeneic stem cell transplantation. Front. Immunol. 10, 1\u201318 (2019).","journal-title":"Front. Immunol."},{"key":"6718_CR47","first-page":"215","volume":"2015","author":"MRM Van Den Brink","year":"2015","unstructured":"Van Den Brink, M. R. M., Velardi, E. & Perales, M. A. Immune reconstitution following stem cell transplantation. Hematol. (United States). 2015, 215\u2013219 (2015).","journal-title":"Hematol. (United States)"},{"key":"6718_CR48","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1080\/21505594.2016.1208866","volume":"7","author":"RS Mehta","year":"2016","unstructured":"Mehta, R. S. & Rezvani, K. Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection. Virulence 7, 901\u2013916 (2016).","journal-title":"Virulence"},{"key":"6718_CR49","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.bbmt.2020.01.005","volume":"26","author":"S Naik","year":"2020","unstructured":"Naik, S. et al. Toward functional immune monitoring in allogeneic stem cell transplant recipients. Biol. Blood Marrow Transpl. 26, 911\u2013919 (2020).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"6718_CR50","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1182\/blood.2023021815","volume":"143","author":"A Mathioudaki","year":"2024","unstructured":"Mathioudaki, A. et al. The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature. Blood 143, 1269\u20131281 (2024).","journal-title":"Blood"},{"key":"6718_CR51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-01952-6","volume":"11","author":"JH von Stemann","year":"2021","unstructured":"von Stemann, J. H. et al. Cytokine autoantibodies are stable throughout the Haematopoietic stem cell transplantation course and are associated with distinct biomarker and blood cell profiles. Sci. Rep. 11, 1\u201310 (2021).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06718-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06718-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06718-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T16:09:40Z","timestamp":1751386180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06718-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6718"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-06718-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"20 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the ethical committee of the Capital Region, Denmark (approval nr H-17024315). All study participants gave informed written consent before inclusion.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"21029"}}